

Supplemental digital content

Univariate and multivariate analysis of predictive factors for persistence of HI titers $\geq 1:40$ at month 12.

	n	Univariateanalysis Odds-ratios (95% CI) ^a	P- value ^b	Multivariateanalysis Odds-ratios (95% CI) ^a	P- value ^b
AS03 _A -adjuvanted vs. unadjuvanted H1N1v vaccine	278	2.45 (1.50-4.01)	0.0004	2.65 (1.59-4.43)	0.0002
HAART vs. without HAART	278	1.79 (1.02-3.13)	0.043	1.73 (0.82-3.63)	0.15
Baseline plasma HIV-1 viral load, log ₁₀ copies/mL	278	0.81 (0.66-0.99)	0.039		
Baseline CD4, ≥ 350 /mm ³	277	0.71 (0.37-1.36)	0.30		
Nadir CD4, per 50 cells/mm ³ higher	278	0.95 (0.89-1.01)	0.12		
Seasonal influenza vaccine 2010 before month 12	278	6.18 (1.40-27.29)	0.016	5.58 (1.23-25.30)	0.026
Seasonal influenza vaccine 2009 prior to H1N1v	278	1.21 (0.72-2.04)	0.47		
HCV and/or HBV co-infection	277	0.81 (0.40-1.65)	0.57		
CDC stage C	278	1.21 (0.67-2.15)	0.53		
Smoker	278	0.54 (0.33-0.88)	0.014	0.57 (0.33-0.96)	0.035
Age < 40 years	278	1.13 (0.65-1.98)	0.66		
Male vs. female	278	0.73 (0.39-1.40)	0.35		

^a Wald confidence interval; ^b Wald chi-square p-value